Journal of Clinical Pathology

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, Mai 9, 2024
MASH, University, Patient, Cirrhosis, Research and development, Liver disease, EASL, Safety, Hypertriglyceridemia, Administration, Journal of Clinical Pathology, Hepatology, Virginia Commonwealth University, PRIME, European Medicines Agency, Liver, Enrollment, EMA, Fibrosis, Division, SAN, Pharmaceutical industry

SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the first quarter ended March 31, 2024.
  • These key clinical developments, coupled with our agreement for commercial supply, are designed to strategically enhance our readiness for potential commercialization."
  • ENLIGHTEN-Cirrhosis, the second trial in the program, is planned to evaluate patients with compensated cirrhosis and is expected to initiate in the second quarter of 2024.
  • As of March 31, 2024, 89bio had cash, cash equivalents and marketable securities of approximately $562.3 million.

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

Retrieved on: 
Donnerstag, Mai 2, 2024
Infection, MASH, Liver disease, Cirrhosis, NAFLD, American Gastroenterological Association, NIH, Publication, Research, Cell Metabolism, Yale University, American Liver Foundation, KOL, Journal of Clinical Pathology, Journal, NASH, Virginia Commonwealth University, Liver, Patient, Fibrosis, AASLD, Internal medicine, Medical Center, Division, SAN, VCU, Pharmaceutical industry

The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH.

Key Points: 
  • The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH.
  • A replay of the webinar will be accessible in the investors section of 89bio’s website following the event.
  • He has also served as Secretary as well as President of the American Association for the Study of Liver Diseases.
  • He has been continuously funded by the NIH since 1995 and is the principal investigator of four active NIH grants.

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Retrieved on: 
Montag, Dezember 11, 2023
Dexmedetomidine, Cardiology, Agitation, FDA, Roche, Actelion, Reata Pharmaceuticals, GSK, Pfizer, IND, Adamas, Medicine, Physician, University, Mount Sinai School, Schizophrenia, Doctor of Philosophy, MEK, Journal of Clinical Pathology, Intermittent explosive disorder, GSK plc, New product development, Caregiver, EMA, Therapy, Patient, Intelligence, Development, Senior, DSM-IV codes, Bipolar disorder, Sanofi, Royal college, Acquisition, Prostate cancer, Clinical trial, Biogen, Pharmaceutical industry

NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company’s strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates.

Key Points: 
  • Vincent J. O’Neill, M.D., Senior Vice President and Chief Research & Development Officer of OnkosXcel Therapeutics, has been promoted to Executive Vice President, Chief of Product Development and Medical Officer of BioXcel Therapeutics.
  • Additionally, Rajiv Patni, M.D., has been appointed to the newly created position of Strategic Clinical Advisor to the BioXcel Therapeutics Chief Executive Officer and Board of Directors.
  • Prior to joining BioXcel Therapeutics, Dr. O’Neill held senior leadership roles at several leading global pharmaceutical companies, including Sanofi, Genentech, and GlaxoSmithKline.
  • “I look forward to working with the BioXcel leadership team in continuing to address the unmet medical needs of patients and caregivers and advance the Company’s product-development goals.”

GenVault Biorepository Announces Executive Director Appointment

Retrieved on: 
Mittwoch, August 9, 2023
Other Transport, Technology, Security, Transport, Chemicals, Plastics, Manufacturing, Networks, Biotechnology, Health, Data Management, Informatics, University, Health administration, Code, Pathology, Foot, Research, Government, Huntsman Cancer Institute, Journal of Clinical Pathology, United States Department of the Air Force, Therapy, Pharmaceutical industry, Science, Biology

GenVault , one of the nation’s most secure, comprehensive commercial facilities for bioinventory storage and transport, announces the appointment of Andrew Lee as executive director.

Key Points: 
  • GenVault , one of the nation’s most secure, comprehensive commercial facilities for bioinventory storage and transport, announces the appointment of Andrew Lee as executive director.
  • Prior to joining GenVault, Lee held leadership roles in biorepository and research informatics at Encoded Therapeutics (focused on transformative gene therapy), and in BMP Biorepository and Molecular Pathology at the Huntsman Cancer Institute.
  • Lee holds both a Bachelor of Science in Biology and a Master of Healthcare Administration from the University of Utah.
  • “We are excited to have Andrew join our team at GenVault.

Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASH

Retrieved on: 
Donnerstag, März 30, 2023
Interim, Non-alcoholic fatty liver disease, Nutrition, Carcinoma, Classification, Liver disease, LACE, Research, MACE, Elastography, Fibrosis, Journal of Clinical Gastroenterology, LSM, HIV disease progression rates, Journal of Clinical Pathology, Patient, Risk, Division, Fatty liver disease, Liver, NAFLD, Mortality, FDA, VCU School of Medicine, Death, Clinical, HCC, Safety, Dietary supplement, Medical imaging, Medicine, Hepatology, Gastroenterology, Physiology

"Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort," was published in the peer-reviewed publication Clinical Gastroenterology and Hepatology .

Key Points: 
  • "Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort," was published in the peer-reviewed publication Clinical Gastroenterology and Hepatology .
  • More than 20% of the US population is affected by NAFLD, which represents a major and growing public health concern with significant health economic implications.
  • While there are no approved curative therapies to date, there are multiple new therapies currently under review with the FDA.
  • Identifying patient populations in the real world who will need these upcoming treatments will be critical when these novel treatments become available.

QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases

Retrieved on: 
Dienstag, Juli 19, 2022
Technology, Research, Genetics, Software, Biotechnology, Health, Pharmaceutical, General Health, Science, Knowledge, AI, Data management, DNA, NGS, AMP, Time, University, AMI, Industry, Protein, U.S. Securities and Exchange Commission, NYSE, SEC, QGEN, Research, Solution, Artificial intelligence, Data analysis, Gene, Certification, Machine learning, Adoption, Automation, Review, NCCN, MD, Patient, Blood, Precision medicine, Life, Heredity, CGP, QCI, Decision-making, Growth, Budget, Journal of Clinical Pathology, RNA, Medical imaging, Medical device, Fine chemical, QIAGEN, Insight, Academy, Pharma

This milestone for the QCI portfolio of clinical software and professional services for the interpretation and reporting of variants from next-generation sequencing (NGS) testing underscores QIAGENs leadership position in precision medicine.

Key Points: 
  • This milestone for the QCI portfolio of clinical software and professional services for the interpretation and reporting of variants from next-generation sequencing (NGS) testing underscores QIAGENs leadership position in precision medicine.
  • The platform, incepted only seven years ago, is currently growing at 35% or 700,000 additional cases per annum, outperforming other commercial offerings by a factor 5 in terms of patient cases.
  • Consisting of QCI Secondary Analysis, QCI Interpret and QCI Precision Insights, the portfolio streamlines NGS data analysis and variant interpretation, enabling users to go from raw NGS data to clinical report swiftly and confidently.
  • Surpassing three million patient cases reported using our QCI solution demonstrates how pervasive our bioinformatics solutions are becoming in the standard of care for patients.

Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022

Retrieved on: 
Freitag, Juni 24, 2022
NASH, Patient, ALT, Adult, Probability, Research, Real world data, Hepatotoxicity, Poster, NAFLD, Liver disease, Division, VCU School of Medicine, Health, Oklahoma Office of the Chief Medical Examiner, Publication, Nutrition, RWE, Therapy, ILC, Cardiovascular disease, Real, Longitudinal, Journal of Clinical Pathology, Entrepreneurship, Hypertension, Non-alcoholic fatty liver disease, Fatty liver disease, Time, Interim, Medical device, Pharmaceutical industry, Medicine, Physiology, Gastroenterology

DURHAM, N.C., June 24, 2022 /PRNewswire/ -- New TARGET-NASH data shows longitudinal trajectories of alanine aminotransferase (ALT) remained comparatively stable among patients with nonalcoholic fatty liver disease (NAFLD) in the latest real-world study by Target RWE .

Key Points: 
  • DURHAM, N.C., June 24, 2022 /PRNewswire/ -- New TARGET-NASH data shows longitudinal trajectories of alanine aminotransferase (ALT) remained comparatively stable among patients with nonalcoholic fatty liver disease (NAFLD) in the latest real-world study by Target RWE .
  • The TARGET-NASH real world study analyzed 3,600+ adult patients with NAFLD in the U.S. with 3 or more ALT measures.
  • "Researchers have not been able to keep pace with the rapidly growing disease burden of NAFLD that is increasing concern from a public health standpoint.
  • Dr. Sanyal is also co-chair of the TARGET-NASH steering committee and is a co-author of the study.

Ninth Annual MongoDB Innovation Award Winners Unveiled at MongoDB World 2022

Retrieved on: 
Dienstag, Juni 7, 2022
Cloud, Goldman Sachs, Vaccination, Cisco Systems, Secop, Record, WHO, Creativity, U.S. News & World Report, Technology, COVID-19, Corva, Memorial Sloan Kettering Cancer Center, Javits Center, Journal of Clinical Pathology, Health, AB InBev, OAuth, Cloud computing, News, Transaction, CEO, Software, MongoDB Inc., Awareness, Solution, Wells Fargo, Cisco Security Agent, Cayman Islands, MongoDB, Industry, FC Avanhard Kramatorsk, NetOps, Carbon, Communication, World, World Health Organization, Occupational burnout, Mental health, CAL, Pathology, Organization, Ultrashort pulse, Hospital, Data, Truist Financial, AB, AT&T, Department, Benchmarking, Science, Ownership, Environment, Forum, MSKCC, Hand, Tempest, NASDAQ, Psychology, AT, Scale, Year, Intelligent Community Forum, Mobile phone, MPlayer.com, Okta

NEW YORK, June 7, 2022 /PRNewswire/ -- MongoDB , Inc. (NASDAQ: MDB), today announced the fifteen winners of the ninth annual MongoDB Innovation Awards.

Key Points: 
  • NEW YORK, June 7, 2022 /PRNewswire/ -- MongoDB , Inc. (NASDAQ: MDB), today announced the fifteen winners of the ninth annual MongoDB Innovation Awards.
  • The winners are being honored during MongoDB World 2022, happening in New York City at the Javits Center, June 7-9, 2022.
  • Certified Professional of the Year Award: Mohit Talniya
    Mohit Talniya works with PeerIslands, a boutique MongoDB SI based out of the Cayman Islands.
  • The MongoDB database platform has been downloaded over 265 million times and there have been more than 1.5 million registrations for MongoDB University courses.

Labcorp Launches New Test for People With Skin Cancer

Retrieved on: 
Mittwoch, Mai 18, 2022
Other Health, Research, Managed Care, Radiology, Pharmaceutical, Oncology, Clinical Trials, Science, Biotechnology, Practice Management, FDA, Health, Physician, Risk, Immunotherapy, Journal, Multimedia, Patient, Solution, Health, Immunohistochemistry, Skin cancer, Clinical trial, Melanoma, MPH, National Cancer Institute, LH, Hospital, Neoplasm, IHC, Journal of Clinical Pathology, Drug development, LinkedIn, Moles, Cancer, NYSE, National, Medical imaging, Pharmaceutical industry, LabCorp

Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company.

Key Points: 
  • Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company.
  • The new test measures Lymphocyte-activation gene 3 (LAG-3) expression levels by immunohistochemistry (IHC) in tumor tissue.
  • The test is available for use in both clinical trials and for the care and treatment of patients.
  • According to the National Cancer Institute, skin cancer is the most common form of cancer in the United States.

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

Retrieved on: 
Mittwoch, Mai 11, 2022
Biotechnology, Health, Clinical Trials, Drug development, Duodenum, Volunteering, Brain, University, Mortality, Wound healing, Lists of diseases, IND, Human, Biosplice Therapeutics, Clinical research, Johns Hopkins University, Blood, Type 2 diabetes, Safety, Journal of Clinical Pathology, Food, Doctor of Philosophy, Patient, Insulin, Disease, Type 1, Program, Glucose, Lipodystrophy, Diabetes, Therapy, University of California, San Diego Performance-Based Skills Assessment, Obesity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Industry, Neurodegeneration, Leadership, Adult, Polymer, Osteoarthritis, Vrije Universiteit Amsterdam, Gastrointestinal disease, GI, Weight loss, Amylin, Liver, Technology, Research, Growth, MCP, Medical research, Medicine, Pharmaceutical industry, Medical imaging, T2D

GLY-200 is a proprietary mucin-complexing polymer (MCP) that enhances the natural mucus barrier in the duodenum (the upper small intestine).

Key Points: 
  • GLY-200 is a proprietary mucin-complexing polymer (MCP) that enhances the natural mucus barrier in the duodenum (the upper small intestine).
  • We aspire to replicate the profound effects of metabolic surgery with a safe, accessible, and affordable oral treatment for patients with metabolic conditions.
  • Our clinical candidate, GLY-200, is optimized to treat patients with T2D and potentially reverse the course of disease.
  • GLY-200 was well-tolerated in a completed Phase 1 trial and is being advanced into Phase 2 development for patients with T2D.